Tactile Systems Technology, Inc. (TCMD) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with significant revenue and income growth. The company has strategic partnerships, increased market awareness, and operational efficiencies driving growth. Despite a decrease in cash due to loan repayment, the underlying cash position improved. The Q&A highlighted strong market strategies and growth drivers, although some specifics were avoided. Overall, the positive financial metrics and strategic initiatives suggest a likely positive stock movement over the next two weeks.
Key Financial Performance
Total Revenue $85.8 million, representing growth of 17% year-over-year. This growth was driven by increases in both lymphedema and airway clearance revenue.
Lymphedema Revenue $72.4 million, increased 11% year-over-year. Growth attributed to execution excellence of the go-to-market commercial strategy and recovery from Medicare documentation challenges.
Airway Clearance Revenue $13.4 million, increased 71% year-over-year. Growth driven by partnerships with top respiratory DMEs, placement agreements, and growing awareness of bronchiectasis treatment options.
Gross Margins 76%, increased by 80 basis points year-over-year. Improvement due to lower manufacturing and warranty costs and stronger collections.
Adjusted EBITDA $14.4 million, increased 34% year-over-year. Growth attributed to operational efficiencies and strategic investments.
Operating Income $11 million, increased 62% year-over-year. Growth driven by revenue increases and controlled operating expenses.
Net Income $8.2 million, increased 59% year-over-year. Growth due to higher revenue and improved operational efficiency.
Cash and Cash Equivalents $66 million at quarter end, compared to $94.4 million at the end of 2024. Decrease due to repayment of term loan, but excluding this, cash balance increased by $9.2 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Flexitouch Plus: Presented 6-month data from a head and neck lymphedema RCT, showing sustained long-term effectiveness compared to usual care. Manuscripts are being prepared for submission.
Nimbl: Continued strong demand with unit growth outpacing market growth. Achieved market leadership in the basic pneumatic, non-pneumatic compression pump category.
Next-generation AffloVest: Submitted a 510(k) to FDA for a lighter, digitally connected, and more adjustable version of AffloVest.
Lymphedema business: Revenue grew 11% year-over-year and 10% sequentially. Medicare channel sales increased 130% year-over-year, while commercial and VA channels declined 9%.
Airway clearance business: Revenue grew 71% year-over-year and 3% sequentially. Partnerships with top respiratory DMEs and growing awareness of bronchiectasis are driving demand.
Sales organization: Expanded field sales team to 329 reps, a 25% increase since Q1, with a balanced distribution of account managers and product specialists.
CRM technology: Implemented advanced CRM tools with market data algorithms and tech enhancements to improve sales efficiency and productivity.
AI-enabled order operations: Piloted AI technology to improve speed and accuracy in order intake and medical record review processes.
Access to care: Focused on clinical evidence generation and AI-enabled order operations to improve patient access and streamline processes.
Expanding treatment options: Launched new products like Nimbl and submitted next-generation AffloVest for FDA review.
Enhancing patient value: Invested in patient services and care navigation pilots to improve engagement and reduce patient leakage.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Documentation Requirements: The company faced challenges due to changes in Medicare documentation interpretation in Q2 2024, which created headwinds throughout the year. Although efforts have been made to adapt, such as launching e-prescribing and reimagining order management processes, these changes have required significant operational adjustments and investments.
Commercial and VA Channels Decline: Sales in commercial and VA channels declined by 9% year-over-year in Q3 2025, attributed to a shift in focus to Medicare patients and the impact of prior-year dynamics. This decline could affect revenue diversification and stability.
Regulatory and Policy Shifts: The transition from LCD to NCD for Medicare patients has introduced new opportunities but also requires significant provider education and adaptation to ensure proper documentation and compliance.
Supply Chain and Tariff Impacts: The company continues to face tariff-related costs, with an estimated $1 million impact in 2025 and ongoing annual impacts of approximately $0.5 million beyond 2025, despite mitigation strategies.
Operational Investments: Significant investments in sales organization expansion, CRM technology, and AI-enabled order operations have been made, but these require ongoing management and could strain resources if not effectively executed.
Market Competition: The company is competing for market share in both the lymphedema and airway clearance segments. While progress has been made, maintaining leadership and growth in these competitive markets remains a challenge.
Economic and Financial Risks: The company has increased operating expenses by 13% year-over-year, driven by strategic investments. While these investments aim to drive growth, they also increase financial risk if expected returns are not realized.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its full-year 2025 total revenue guidance to a range of $317 million to $321 million, representing growth of approximately 8% to 10% year-over-year.
Lymphedema Product Growth: Growth for lymphedema products is expected to be 3% to 4% for the full year 2025.
Airway Clearance Product Growth: Growth for airway clearance products is expected to be 52% to 55% for the full year 2025.
Medicare Policy Impact: The transition from the LCD to the less restrictive NCD is expected to expand access to advanced pump therapy, benefiting patients with complex lymphedema. Positive impacts are expected in Q4 2025, with more momentum building into 2026.
Adjusted EBITDA Guidance: Adjusted EBITDA is expected to be approximately $38 million to $39.5 million for 2025.
Gross Margin: GAAP gross margin is expected to be approximately 75% for the full year 2025.
Operating Expenses: GAAP operating expenses are expected to increase approximately 11% year-over-year in 2025, driven by investments in the sales organization and technology.
Tax Rate: The tax rate for 2025 is expected to be 28%.
Tariff Impact: The full-year tariff impact is expected to be approximately $1 million in 2025, with an ongoing annual impact beyond 2025 of roughly $0.5 million if no further changes occur.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company announced the initiation of a second share repurchase program of up to $25 million of outstanding stock. This decision aligns with the company's confidence in its business trajectory and its ability to execute financial and operational initiatives. The company emphasized that its strong balance sheet provides flexibility for meaningful capital deployment to drive growth and increase shareholder value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What continues to drive the strong performance of AffloVest?
A:The strong performance of AffloVest is driven by three strategies: deep relationships with the top 10 DMEs, increased awareness of bronchiectasis through medical education, and having a differentiated product that is taking market share. The revenue contribution from AffloVest increased to 16% from 11% last year. The company has preferred product positions in several DMEs, good alignment on inventory, and a healthy supply chain. Awareness is also growing due to medical education provided to DMEs and clinicians.
Q:What is AffloVest's market share and how is the market growing?
A:While specific market share details were not provided, the company believes it is a close #1 or has already overtaken Baxter as the market leader. The market is growing in double digits, driven by increased awareness of the disease and complementary pharmaceutical products. There are 5 million underserved patients in this market.
Q:What are the drivers of lymphedema revenue growth and the impact of the NCD?
A:Lymphedema revenue growth is driven by expanded headcount (66 additional reps, a 25% increase), increased productivity, and the impact of the NCD. The NCD allows patients with specific conditions to go directly to advanced pump therapy like Flexitouch without a 4-week basic pump trial. The company raised its lymphedema growth guidance to 3%-4% for the year.
Q:What are the company's expectations for lymphedema market growth in 2026?
A:The lymphedema market is growing at 10%, and the company expects to perform in line with the market. The company has raised its guidance for this year to 8%-10% growth and believes its investments in sales headcount, CRM tools, and back-office support will sustain this growth.
Q:What are the key initiatives driving growth across the business?
A:Key initiatives include optimizing the sales force with a 1:1 ratio of account managers to product specialists, leveraging CRM tools for productivity, and benefiting from the NCD policy. The company is also seeing efficiencies in the back office and strong performance from both AffloVest and lymphedema products.
Q:What is the company's strategy for sales force expansion and the impact of the NCD?
A:The company has expanded its sales force to 329 reps, exceeding its goal of 300. It plans to continue adding headcount based on territory growth. The NCD provides a pathway for patients with specific conditions to access advanced pump therapy directly, which is expected to drive growth.
Q:What is the impact of the first bronchiectasis drug approval on the market?
A:The approval of the first bronchiectasis drug has increased market awareness and diagnoses, benefiting the overall market. The company believes this has created an uplift in awareness and market share growth.
Q:What are the company's efforts regarding payer policies for head and neck lymphedema?
A:The company is engaging with commercial payers to address policies that classify head and neck lymphedema as experimental. While policy changes are expected in 2026, the company is using its data and studies to advocate for coverage changes.
Q:What is the expected impact of strategic optimizations and tech upgrades?
A:Strategic optimizations and tech upgrades, such as the CRM tool and sales force expansion, are already showing benefits in productivity and efficiency. The company plans to continue investing in these areas, with returns expected in late 2026 and into 2027.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on AffloVest's market share, the exact growth rate of the bronchiectasis market, and the specific mix of Nimbl versus Flexitouch in lymphedema revenue. Additionally, they did not provide guidance for 2026 but indicated confidence in aligning with market growth rates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA
Nimbl
Tactile
account manager
addition
airway clearance
care market
care navigation
clearance line
communication
comparison
compression pump
demand
effectiveness Flexitouch
enhancement
evidence generation
field
generation AffloVest
generation product
infrastructure
leverage
loan
manuscript
market position
momentum
navigation pilot
order intake
partnership
patient information
payer mix
period
plan
process order
product AffloVest
product demo
productivity
record
repayment
review process
site
transition
update priority
TCMD Transcript
Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call reveals strong financial performance with significant revenue growth, improved gross margins, and a turnaround from a net loss to net income. Operating expenses increased due to strategic investments, indicating a focus on growth. Despite risks mentioned, the financial metrics and positive EBITDA growth suggest a favorable outlook. The absence of negative sentiment in the Q&A further supports a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
Tactile Systems Technology, Inc. (TCMD) Q4 2025 Earnings Call Transcript
Positive2-18
The company's strong Q4 financial performance, including a 21% revenue increase and improved margins, reflects positive momentum. Raised revenue guidance and successful product growth in airway clearance further bolster sentiment. While there are concerns regarding Medicare prior authorization, the company's strategic investments and partnerships mitigate risks. The Q&A section reveals cautious optimism and readiness to address challenges, supporting a positive outlook. Overall, the combination of strong financials and strategic growth initiatives suggests a likely positive stock price movement in the near term.
Tactile Systems Technology, Inc. (TCMD) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call shows strong financial performance with significant revenue and income growth. The company has strategic partnerships, increased market awareness, and operational efficiencies driving growth. Despite a decrease in cash due to loan repayment, the underlying cash position improved. The Q&A highlighted strong market strategies and growth drivers, although some specifics were avoided. Overall, the positive financial metrics and strategic initiatives suggest a likely positive stock movement over the next two weeks.
Tactile Systems Technology, Inc. (TCMD) Q2 2025 Earnings Call Transcript
Unknown8-4
The earnings call reflects a mixed sentiment. The company shows positive signs with strong product launches (Nimbl, AffloVest) and strategic initiatives (CRM, AI tools), but faces challenges such as increased operating expenses and commercial channel weakness. Despite exceeding Q2 expectations, guidance was only slightly raised, indicating cautious optimism. The Q&A reveals uncertainties in policy updates and market share data. The stock buyback and cash position are positives, but the overall sentiment remains balanced, leading to a neutral prediction for stock price movement.
TCMD Slides
TCMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
